10x Genomics (TXG) Misses Q3 EPS by 33c, provides guidance

10x Genomics (NASDAQ: TXG) reported Q3 EPS of ($0.79), $0.33 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $153.6 million versus the consensus estimate of $151.3 million.

GUIDANCE:

10x Genomics sees Q4 2023 revenue of $610-625 million, versus the consensus of $409.7 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• AeroVironment restates quarterly financials, citing $89M goodwill error
• Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins